Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease
β Scribed by L. Morgante; A. Epifanio; E. Spina; A.E. Di Rosa; M. Zappia; G. Basile; P. La Spina; A. Quattrone
- Publisher
- Springer Milan
- Year
- 2002
- Tongue
- English
- Weight
- 37 KB
- Volume
- 23
- Category
- Article
- ISSN
- 1590-1874
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Clozapine has been shown not only to be effective in ameliorating dopaminomimetic psychosis but to improve parkinsonian symptomatology. Six parkinsonian patients with motor fluctuations under levodopa treatment and severe interdose βoffβ periods (believed to be mediated by an inhibitory
## Abstract Due to its low profile for extrapyramidal sideβeffects, quetiapine has become an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease (PD). We describe the case of a patient with PD who developed severe akathisia, a common complication
## Objective The objective of this study was to assess the safety and tolerability of extendedβrelease quetiapine fumarate (quetiapine XR) compared with quetiapine immediateβrelease (quetiapine IR) in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation. ## Methods